基本情報
- CAS
33286-22-5- 標準SMILES
COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1.Cl- InChIKey
HDRXZJPWHTXQRI-BHDTVMLSSA-N- 分子式
- C22H27ClN2O4S
- 平均分子量
- 451 g/mol
- 単同位体質量
- 450.13800602
概要
Diltiazem Hydrochloride can cause developmental toxicity according to state or federal government labeling requirements.
名称と識別子
- 優先名称
- Diltiazem Hydrochloride
- IUPAC
- [(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate;hydrochloride
- 現地名
- (+)-cis-ジルチアゼム塩酸塩
- 英語名
- Diltiazem hydrochloride
- 分子式
- C22H27ClN2O4S
- 分子量
- 450.98
名称と別名
Diltiazem hydrochloride33286-22-5Diltiazem HClAdizemDilzemDilzeneMasdilAltiazemDeltazenDiladelDilpralDilrene
名称をさらに表示
(+)-cis-ジルチアゼム塩酸塩(2S)-3β-(アセチルオキシ)-5-[2-(ジメチルアミノ)エチル]-2,3-ジヒドロ-2β-(4-メトキシフェニル)-1,5-ベンゾチアゼピン-4(5H)-オン·塩酸塩ヒロスタスRヨウチアゼムパゼアジンセレスナットカルナース塩酸ジルチアゼムマルムネンジルベイトヘルベッサーミオカルジーヘルベッサー-R酢酸(3S)-[(2S)-5-[2-(ジメチルアミノ)エチル]-2,3,4,5-テトラヒドロ-2β-(4-メトキシフェニル)-4-オキソ-1,5-ベンゾチアゼピン]-3β-イル·塩酸塩パゼアジン-Rジルチアゼム塩酸塩ジルチアゼム·塩酸塩ヘマレキートコーレンフロッティDILTHIAZEM HYDROCHLORIDETiazacherbesserDiltiazem HydrochloridSprixAcuvailcardizem
物性
構造計算による物性
- 極性表面積
- 84.4 Ų
- 水素結合供与体数
- 1
- 水素結合受容体数
- 6
- 回転可能結合数
- 7
- 重原子数
- 30
- 形式電荷
- 0
- 複雑度
- 565
実験および物理化学的性質
Human Drugs
Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Calcium Channel Blockers; Antiarrhythmics; Vasodilator Agents
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Collision Cross Section196.1 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
物理化学的性質
- 融点
- 212 · 212-214 °C
- 比旋光度
- 24 · D24 +98.3 ± 1.4° (c = 1.002 in methanol)
- 比重(密度)
- 1.3 g/cm3 · 1.30 g/cm3
- 屈折率
- 118 ° · 118 ° (C=1, H2O)
- 闪点
- 2 ℃ · 2℃
- 貯蔵温度
- 2 · 2-8°C
- 溶解性
- 水、メタノール、塩化メチレンに溶けやすく、無水エタノールに溶けにくい。
- 外見
- 粉
- 色
- ホワイトからオフホワイト
- PH
- pH (10g/l, 25℃) : 4.3～5.3
- 水溶解度
- 溶ける
- Merck
- 13 · 13,3226
- BRN
- 4228706 · 4228706
- 安定性
- -20 °Cで最大3か月保存できます · DMSOまたは蒸留水の溶液で-20°Cで最大3か月保存できます.
安全と法規制
GHS分類
GHS Classification
Warning
H302 (99.2%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P264, P270, P280, P301+P317, P318, P330, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 119 reports by companies from 16 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
危険有害性情報
Regulatory Information
Hazard Traits - Developmental Toxicity
Diltiazem hydrochloride: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, monohydrochloride, (2S-cis)-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (99.2%)
毒性情報
Treatment
In the event of overdose or exaggerated response, appropriate supportive measures should be employed in addition to gastrointestinal decontamination. If bradycardia and/or high-degree AV block occurs, administer atropine (0.60 to 1.0 mg). If there is no response to vagal blockage, administer isoproterenol cautiously. Fixed high-degree AV block should be treated with cardiac pacing. In cases of cardiac failure, administer inotropic agents (isoproterenol, dopamine, or dobutamine) and diuretics. If hypotension occurs, use vasopressors (e.g. dopamine or levarterenol bitartrate). (L1712)
Health Effects
Because of its negative inotropic effect, diltiazem causes a modest decrease in heart muscle contractility and reduces myocardium oxygen consumption. Its negative chronotropic effect results in a modest lowering of heart rate, due to slowing of the sinoatrial node. It results in reduced myocardium oxygen consumption. Because of its negative dromotropic effect, conduction through the AV (atrioventricular) node is slowed, which increases the time needed for each beat. This results in reduced myocardium oxygen consumption. A reflex sympathetic response, caused by the peripheral dilation of vessels and the resulting drop in blood pressure, works to counteract the negative inotropic, chronotropic and dromotropic effects of diltiazem. Undesirable effects include hypotension, bradycardia, dizziness, and flushing. (Wikipedia)
化学と産業
薬理情報
Metabolism/MetabolitesDiltiazem is metabolized by and acts as an inhibitor of the CYP3A4 enzyme.
Half Life: 3.0 - 4.5 hours
FDA Pharmacological Classification
DILTIAZEM HCI
Calcium Channel Blocker [EPC]; Calcium Channel Antagonists [MoA]; Cytochrome P450 3A4 Inhibitors [MoA]
DILTIAZEM HCL ER
Cytochrome P450 3A4 Inhibitors [MoA]; Calcium Channel Antagonists [MoA]; Calcium Channel Blocker [EPC]
DILTIAZEM HYDROCHLORIDE
Calcium Channel Blocker [EPC]; Calcium Channel Antagonists [MoA]; Cytochrome P450 3A4 Inhibitors [MoA]
MeSH Pharmacological Classification
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
A class of drugs that act by selective inhibition of calcium influx through cellular membranes.
Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.
Drugs used to cause dilation of the blood vessels.
用途と製造
UsesFor the treatment of hypertension.
応用分野
用途カルシウム拮抗剤です。L型 電位依存性カルシウムチャネルのD部位に結 合し、細胞内へのカルシウムイオン流入を抑 制する作用を示します。
用途カルシウム拮抗剤です。L 型 電位依存性カルシウムチャネルのD 部位に結 合し、細胞内へのカルシウムイオン流入を抑 制する作用を示します。
用途薬理研究用。
使用An antianginal, antihypertensive. Regulates Calcium release from intracellular stores in neutrophils
Diltiazem hydrochloride is a calcium ion cellular influx inhibitor. It was developed and introduced inJapan as a cardiovascular agent to treat angina pectoris. Itwas observed to dilate peripheral arteries and arterioles. Thedrug increases myocardial oxygen supply by relieving coronaryartery spasm and reduces myocardial oxygen demandby decreasing heart rate and reducing overload. Diltiazemhydrochloride is used in patients with variant angina. Thedrug has electrophysiological properties similar to those ofverapamil and is used in clinically similar treatment conditionsas an antiarrhythmic agent, but it is less potent.The drug is absorbed rapidly and almost completely fromthe digestive tract. It reaches peak plasma levels within 1hour after administration in gelatin capsules. Oral formulationson the market are sustained-release preparations providingpeak plasma levels 3 to 4 hours after administration.
関連反応
7 件
化合物ノート
読み込み中…